L&P Client Argentum Pharmaceuticals Granted Joinder in IPR

Argentum Pharmaceuticals LLP, represented by Laurence & Phillips IP Law, filed a petition on March 10, 2017 for inter partes review (IPR) in IPR2017-01063 against U.S. Patent No. 9,006,224, which is owned by Novartis AG and is titled “Neuroendocrine Tumor Treatment.”  The petition was accompanied by a motion for joinder, which was granted today. L&P partner Kevin Laurence is lead counsel for Argentum in the IPR.